Marsh william

  • High Potency API/HPAPI Market to Reach $34.8 Billion by 2025 | Grand View Research

    The global HPAPIs market is expected to reach USD 34.8 billion by 2025, according to a new report by Grand View Research, Inc. Increasing number of new entrants producing fast relief therapeutics in emerging countries of India and China is anticipated to boost the demand for High potency active pharmaceutical ingredients (HPAPIs) over the forecast period. 

    In addition, supportive government regulations for commercialization and research and development of novel drug molecules are projected to drive the industry growth. Extensive capital investments required for development of production facility has lead to increase in contract manufacturing activities for HPAPIs during the forecast period.

    Further Key Findings From the Study Suggest: 

    • Synthetic route of High PotencyAPIs dominated the overall market in terms of revenue share as of 2016 owing to presence of large manufacturers producing these type of molecules
    • Biotech HPAPI segment is expected to be the fastest growing and is expected to grow at a lucrative growth ratedue torising demand for cancer drugs and fueling research and developmentactivities pertaining to it
    • Innovative drug market dominated the overall drug type in 2016. Generic drug segment is expected to be the fastest growing segment. The factors attributing to its growth are patent expiration of various drugs and increasing demand for the cancer treatment
    • Contact outsourcing segment is anticipated to show lucrative growth as major pharmaceuticals are focused on rigorous research and development activities for new drug development
    • Oncology segment heldlargest revenue share as of 2016, due to increasing demand for anti-cancerous drugs
    • North America HPAPIs market held the largest market share as of 2016. Growing prevalence of chronic disease patients, and established research and development infrastructure for novel drug development are factors supporting to major share of this market
    • Patent expiration of major drugs in North American and European countries is anticipated to fuel market growth
    • Asia Pacific regional market is expected to register significant growth owing to growing investments in biotechnology sector and rapidly growing oncology market
    • The key players in the HPAPI market includeBristol-Myers Squibb, Sigma-Aldrich Corporation, Pfizer Incand Lonza among others
    • Extensive research and development activities carried out by market participants is also expected to augment the market growth

    Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/high-potency-active-pharmaceutical-ingredients-hpapi-market


  • Complementary & Alternative Medicine Market to Reach $210.81 Billion by 2026

    The global Complementary And Alternative Medicine Market size is expected to generate a revenue of USD 210.81 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 17.07% during the forecast period. Factors such as the increasing adoption and usage of natural supplements/wellness medicine coupled with government initiatives to promote adoption of the therapy is expected to create revenue generation avenues.

    Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period.

    Approximately two third population of most of the developed and developing countries has reported using one or the other form of alternative or complementary medicine. Certain countries are moving towards legalization of some alternative medicine and therapies backed with approved clinical data.

    Further key findings from the report suggest:

    • The market is driven by high adoption of herbal dietary supplements and other wellness therapies like yoga, and acupuncture
    • Botanical has become the most prominent form of alternative medicine as the segment was observed to hold the largest market share in terms of revenue 2018
    • Europe and Asia Pacific in combination are anticipated to hold a major market share in terms of revenue over the forecast period
    • Developing regions such as Latin America and Middle East Africa are set to witness considerable growth in demand over the forecast period driven by high cost of conventional medicine and lack of their availability in certain countries
    • Some of the key players and wellness institutes active in the complementary and alternative medicine market are Columbia Nutritional Inc.; Herb Pharm; Herbal Hills; Helio USA Inc.; Deepure Plus; Nordic Naturals; Pure encapsulations, Inc.; and other wellness institutes like Iyengar Yoga Institute; John Schumacher’s Unity Woods Yoga Center; Yoga Tree; The Healing Company; and Quantum Touch Inc.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/aternative-medicine-therapies-market


  • Electrophysiology Devices Market to Grow at a CAGR of 5.0% to 2020

    Electrophysiology Devices Industry is anticipated to grow at a CAGR of over 5.0% and reach over USD 6.18 billion by 2020 owing to growing old age population and frequent cardiac arrhythmias incidents. Adoption of ablation and diagnostics techniques among physicians has resulted in increased usage of the product in the past few years and is likley to drive market growth. Development of new devices such as nanostimleadless pacemaker is also anticipated to fuel demand in the market. 

    Catherer ablation has gained popularity as the first line treatment, rendering 95.0% success rate for several rhythm disorders and is anticipated to be a key driving factor for growth. Diagnostic electrophysiology catheters are estimated to grow at the CAGR of over 15.0% in the foreseeable future.Technological developments such as laser ablation, cryo-ablation and ultrasound ablation, coupled with optimised mapping techniques are anticipated to augment market growth over the forecast period. 

    Electrophysiology treatment & monitoring devices contributed to a share of over 60.0% of in 2013. X-ray systems was the most widely used device in electrophysiology monitoring sector. Market growth can be attributed to improving diagnostic interventional capabilities of healthcare consultants and increasing usage of digital and portable systems. Technological improvements such as Optima IGS 320 and GE Healthcare’s Innova IGS 520 are projected to provide future opportunities for growth. These are dose efficient products and interventional X-ray systems that allow physicians to perform compound interventional procedures with accuracy and ease. 

    Electrophysiology treatment devices include pacemakers, implantable cardioverter defibrillators (ICD) and catheters. Catheters emerged as the largest treatment devices segment in 2013 owing to growing number of interventional procedures and extensive usage of treatment devices in electrophysiology readings. However, rising costs related with the product, existence of strict regulations and accessibility of substitute therapies are anticipated to hamper growth over the forecast period.

    In 2013, North America contributed to over 30.0% of the overall market share and emerged as the dominant market owing to frequent occurrence of cardiac arrhythmia resulting from unhealthy lifestyle habits. Increasing demand for the latest healthcare infrastructure and rising consumer awareness are anticipated to propel growth.

    Asia-Pacific is a lucrative market owing to high rate of unmet medical requirements leading to increase in the number of patients. Rapid developments in healthcare infrastructure and increase in disposable income in emerging economies such as India and China are expected to provide new avenues and opportunities for companies to capitalize over the forecast period.

    Key electrophysiology device manufacturers include Biotronik SE & Co. KG, Medtronic Inc., St. Jude Medical, Boston Scientific Corporation and Abbott Laboratories.

    Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/electrophysiology-devices-market


  • Global Pacemaker Market is Projected to Reach $10.3 Billion by 2025 | Grand View Research

    The global Pacemaker Market size is expected to reach USD 10.3 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 7.2% CAGR during the forecast period. Heightening prevalence of cardiac conditions, coupled with rising availability of medical coverage, is a key driving factor governing the growth of the pacemaker market globally. In addition, technological enhancements in these devices are supporting market expansion.

    Increasing prevalence of cardiovascular diseases (CVDs) is a high-impact growth-rendering factor. The World Health Organization reported an estimated 17.5 million deaths stemming from CVDs in 2012. Currently, high occurrence of CVDs is a key concern and in order to address this, government organizations and market participants are channelizing funds and efforts to offer the best possible cure. This is anticipated to foster R&D initiatives and increase the influx of advanced products in this marketspace.

    Additionally, increasing awareness about cardiovascular disorders and their long-term impact is raising the preference of patients for advanced treatment options. This is expected to bolster the usage rate of these products. On the other hand, these devices are cost prohibitive, with the price of a pacemaker ranging from USD 10,000 to USD 30,000. This is likely to restrain the growth of the market.

    Further key findings from the study suggest:

    • Implantable pacemakers held a lucrative share in 2016 and are likely to grow at a profitable rate over the forecast period
    • North America, owing to its planned healthcare network, greater per capita income, and increasing awareness levels about adverse effects of a prolonged cardiac condition, has retained a large share in the global pacemaker market
    • Economic development in countries such as India and China, unmet needs of a massive population, and supportive initiatives undertaken by governments to improve healthcare access are projected to present avenues for investment in the Asia Pacific market
    • Some of the key players operating in this space are Medtronic; BIOTRONIK, Inc.; Boston Scientific Corporation; St. Jude Medical; ZOLL Medical Corporation; MEDICO S.p.A.; Vitatron; Pacetronix; and Cordis, Inc.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/pacemaker-market


  • Microfluidics Prototype Market to Reach $1.8 Billion in 2025 | Grand View Research

    The global Microfluidics Prototype Market size is expected to reach USD 1.8 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 20.54% over the forecast period. Introduction of advanced technologies, increasing demand for low volume sample analysis, and emergence of 3D printing technology are among the key factors likely to drive the market during the forecast period.

    The microfluidics prototype market is anticipated to witness high growth in the forthcoming years due to increasing investment by key market players to expedite technological innovations in the developing industry. In July 2018, TechX Pioneer Program of the Oil and Gas Technology Center, awarded RAB Microfluidics with a 12-month fellowship platform including business development training, mentorship from business consultants, and funding aid. The grant was made for the development of a miniature lab-on-chip technology for rotating equipment offering predictive failure analysis and real-time condition monitoring.

    The development of microfluidics devices involves a high operational cost due to functions, such as microfabrication. Moreover, most of the prototyping methods for microfluidics devices are not compatible with batch process. The scale-up of this method is a costly and complicated affair. This has led to an emphasis on the development of cheaper systems. For instance, in March 2018, researchers from the National University of Singapore (NUS) developed a microfluidic chip that can detect nano-bioparticles without the use of fluorescent labels providing disease diagnosis at a low cost.

    Rising research and development activities are anticipated to bode well for market growth in Asia Pacific. For instance, in India, the Microfluidics and Biological Physics Group of Indian Institute of Technology Bombay uses microfluidics technology to build point-of-care diagnostic platforms. The team uses conventional microfluidic devices and different alternate substrates to design and develop affordable lab-on-chip platforms.

    The global market for microfluidics prototype is startup-driven and is highly supported by government and private institutions. For instance, in October 2017, the National Institute of Health, USA, awarded Neofluidics with a Phase 1 Small Business Innovation Research (SBIR) grant of USD 175,000. The grant was allotted to develop a microfluidic device for drug screening and disease modeling studies using zebrafish embryos.

    Further key findings from the report suggest:

    • Introduction of advanced technologies, increasing demand for low volume sample analysis, and emergence of 3D printing technologyare expected to propel the market at a CAGR of 20.54% from 2018 to 2025
    • North America held the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to the presence of more than 170 service providers, abundant funding opportunities, and R&D investments
    • Asia Pacific region is anticipated to spearhead the market in terms of growth rate over the forecast period. Presence of university research groups and spinoffs contribute significantly to the growth.
    • Key contributors in microfluidics prototype market are microLIQUID; thinXXS Microtechnology; Potomac; uFluidix; Alvéole; Micronics, Inc.; ALine, Inc.; and research groups from various universities.

    Browse Details of Report @

    https://www.grandviewresearch.com/industry-analysis/microfluidics-prototype-market


  • Acromegaly Treatment Market to Reach $2.10 Billion by 2025 | Grand View Research

    The global Acromegaly Treatment Market size is expected to reach USD 2.10 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 7.5% over the forecast period. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

    Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

    The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

    Further key findings from the report suggest:

    • Somatostatin analogs segment is expected to emerge as the largest product segment in terms of revenue share in the forthcoming years, owing to easy availability and cost-effective treatment procedure of the product
    • Hospital and clinics end use segment accounted for the largest market share as all the surgical procedures are performed in these facilities. Easy availability of surgeons Is anticipated to further drive the segment
    • North America held the dominant market share in 2018, due to favorable government insurance policies and increased investment in R&D by the pharmaceutical companies. For instance, In May 2018, U.S. Congress approved the Right to Try bill, wherein patients can try unproven medical therapeutics in case of serious illness including orphan diseases like acromegaly
    • Asia Pacific acromegaly treatment market is anticipated to witness lucrative growth in near future due to rising healthcare expenditure and R&D initiatives by pharmaceutical companies
    • Some of the key players are Novartis AG; Ipsen Pharma; Pfizer Inc.; and Chiasma Inc.

    Browse Details of Report @

    https://www.grandviewresearch.com/industry-analysis/acromegaly-treatment-market


  • Breakthrough Therapy Designation Market to Reach $144.6 Billion By 2025

    The global Breakthrough Therapy Designation Market is anticipated to reach USD 144.6 billion by 2025, according to a new report by Grand View Research, Inc. Breakthrough Therapy (BT) designation is granted to drugs that display substantial results in the treatment of life-threatening diseases in initial stages of the drug development process. Expedited regulatory process in North America and EU regions is driving growth. Increase in the number of innovative molecules receiving the BT status, coupled with rise in the demand for orphan drugs as well as those for the treatment of cancer, is anticipated to boost the market over the forecast period.

    The development time of BT therapy is 30.0% to 50.0% lesser than those without the designation. This significantly increases the net present value of investigational molecule. Reduction in the development time of these drugs is expected to accelerate their approval process as compared to standard drugs as well as boost growth opportunities. The BT tag also increases the value of the drug due to its high scientific value.

    There has been a consistent rise in the number of drugs receiving BT status in the U.S., and this trend is also expected to drive the number of applications submitted for the same, thereby contributing to the market growth.

    Further Key Findings From the Study Suggest:

    • The infectious diseases segment dominated the market in 2016. However, it is expected to exhibit moderate growth in the forecast period owing to decline in sales of blockbuster drugs such as Harvoni and Sovaldi
    • Oncology is expected to be the dominating segment over the forecast period owing to rise in the demand for cancer medicines and increase in the number of oncology molecules gaining BT status. As of 2017, the number of molecules gaining BT status is the highest in this segment
    • The rare diseases segment is estimated to exhibit fastest growth owing to rise in demand and increase in the R&D pipeline of orphan drugs
    • North America is expected to dominate the market over the forecast period owing to well-established intellectual property laws and preference of patients and healthcare professionals for innovative medicines
    • Some of the key players are F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Pfizer, Inc.; AbbVie, Inc.; Janssen Global Services, LLC; Bristol-Myers Squibb Company; Eli Lilly and Company; Sanofi; Regeneron; AcadiaPharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Amgen, Inc.; AstraZeneca; and GlaxoSmithKline plc.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/breakthrough-therapy-bt-designation-market


  • Tissue Expanders Market is Projected to Grow at a CAGR of 5.5 % by 2025

    The global Tissue Expanders Market is anticipated to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. This growth can be attributed to increase in the number of reconstruction surgeries.

    Growing concern among people regarding their physical appearance has led to a rapid growth of the tissue expanders market. In the U.S., over 102,200 breast reconstruction procedures were performed in 2014, which showcase a 7% rise from the previous year, as estimated by the American Society of Plastic Surgeons. In addition, cleft lip surgeries that are prevalent among the pediatric population also require tissue expanders. Thus, rise in the number of these surgeries has led to a huge growth of this market.

    According to the Agency for Healthcare Research and Quality, the percentage of women undergoing mastectomy procedures has increased by 36% from 2005 to 2013. Thus, growing number of mastectomies is anticipated to drive the demand for tissue expanders. In addition, burns and road accidents result in severe scars or deformities, which most often require surgical treatment. Hence, there is a steep rise in the number of reconstructive surgeries that make use of tissue expanders for such severe scars or deformities, which aids in market growth.

    Further Key Findings From the Study Suggest:

    • In 2016, breast reconstruction held the largest market share owing to large number of breast reconstruction surgeries performed
    • Forehead skin and scalp reconstruction is anticipated to witness lucrative growth over the forecast period due to increase in number of cicatricial alopecia cases
    • Anatomical-shaped tissue expanders dominated the market in 2016 due to their natural-looking appearance
    • Round-shaped expanders are expected to display fastest growth over the forecast period due to lower risk of expander ripples through the skin
    • Hospitals held the largest revenue share in 2016 due to large number of reconstruction surgeries being performed in hospitals
    • Cosmetology clinics are anticipated to witness significant growth over the forecast period due to the huge demand for specialty clinics for reconstructive procedures
    • North America dominated the market in 2016 due to increase in the number of reconstruction surgical procedures being conducted in this region
    • Asia Pacific is projected to exhibit fastest CAGR over the forecast period due to increase in road accidents and trauma cases in this region and developing healthcare infrastructure
    • Some of the major companies in the market are Mentor Worldwide LLC; Sientra, Inc.; Allergan; GROUPE SEBBIN SAS; Eurosilicone; and KOKEN CO., LTD.

    Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/tissue-expander-market


  • Population Health Management Market is Expected to Grow USD 101.0 Billion by 2025

    The global Population Health Management Market size is expected to reach USD 101.0 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 20.7% during the forecast period. The need for population health services that combine multiple functionalities is increasing, due to the complex nature of care delivery and payment models. PHM solutions can process clinical, financial, and operational data for the improvement of efficiency and patient care. The convenience offered by value-based payment models instead of Fee-for-Service (FFS) is responsible for increased adoption of these solutions by the Accountable Care Organizations (ACOs).

    ACOs, consist of hospitals, clinics, doctors, and other caregivers, collaborate with payers for the delivery of high-quality patient care. Private and public insurance providers have introduced various disease management programs, to assist in the treatment of chronic illnesses. These multidisciplinary efforts are expected to result in effective treatment outcomes and are likely to suggest best suitable courses of action that need to be undertaken. Successful large-scale trials in U.S. have enabled significant advancements in disease management programs.

    The market has a healthy mix of vendors offering PHM along with other healthcare IT solutions. Acquisitions and partnerships are the major strategies adopted by the companies operating in the population health management market. For instance, in 2018 Allscripts announced completion of acquisition of the HealthGrid Holding Company, a developer of enterprise patient engagement solution. The acquisition signifies expansion of the Allscripts FollowMyHealth platform that provides patient engagement solutions focused on connecting consumers with providers. 

    Further key findings from the report suggest:

    • Based on the products, the services segment held majority of the market share in 2018, as healthcare providers prefer in-house maintenance services
    • In 2018, healthcare provider held the largest market share of the end-use segment. The providers can focus effectively on patient-centric care and reducing overall costs
    • North America was the largest regional market in 2018 and is likely to retain its position over the forecast period, as the providers, payers, providers-payers, and accountable care organizations promote the use of PHM services
    • Asia Pacific is expected to witness the fastest growth in the forthcoming years due to rising healthcare expenditure and improving healthcare infrastructure
    • Allscripts, McKesson Corporation, and Cerner Corporation among others are some of the key players operating in the Population Health Management (PHM) market. Business partnerships and acquisitions are some of the key strategic initiatives undertaken by these companies to strengthen their market presence.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/population-health-management-phm-market


  • Neurodiagnostics Market Size Projected To Reach $18.3 Billion By 2024 |Grand View Research

    The global Neurodiagnostics Market was valued at 13.6 billion in 2015 and is expected to reach a value of USD 18.3 billion by 2024, according to a new report by Grand View Research, Inc. Key factors driving the market growth include increasing prevalence of neurological diseases due to demographic changes and growing awareness of their management. In addition, consistent technological modifications coupled with increased preference for novel diagnostic technologies will further fuel the market. The economic burden of neurological diseases is extremely high on society and governments with around 1 billion people suffering globally.

    Among all the neuroimaging techniques, computed tomography has the largest market share followed by Magnetic Resonance Imaging (MRI). Computed Tomography (CT) uses ionized radiations for the purpose of creating images, whereas MRI uses radio waves in a magnetic field. Neuroimaging techniques are used to detect brain injuries, developmental malformations in the brain area, vascular irregularities that may lead to stroke, epilepsy, etc.

    Biomarkers are an important part of in vitro diagnostics for neurological disorders as their development is targeted at the early disease diagnosis with information about nervous system. Although biomarkers are not commercially available in the market, their use is confined to clinical research settings. For instance, ELISA tests for Tau protein are available in clinical studies of Alzheimer’s disease. In addition, neuroinformatics is a field that studies neuroscience and information technology. This integration allows the storage of neurological data in the form databases. The neuroinformatics market is expected to grow at second highest growth rate during the forecast period.

    Further Key Findings From the Study Suggest:

    • Increased life expectancy has resulted in increased geriatric population across the globe. The prevalence of aging-related neurological diseases such as Alzheimer’s disease and Parkinson’s disease is on the rise. The diagnosis of these diseases includes neuroimaging, in vitro diagnosis, and neuroinformatics.
    • CT and MRI are the most commonly used imaging techniques across the globe, which are mainly used to detect brain abnormalities.
    • Neurological biomarkers are extremely promising as they provide a direction to the diagnostic studies. Although currently no commercial biomarker is available in the market, an extensive clinical research is happening to find out the perfect combinations of the biomarkers.
    • North America held the major market share of around 36% in the year 2015 and will retain its top position during the forecast period. On the other hand, Asia Pacific will exhibit highest CAGR of 4% over the forecast period. 

    Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/neurodiagnostics-market


  • Bone Grafts and Substitutes Market to Reach $3.9 Billion by 2025 | Grand View Research

    The global Bone Grafts And Substitutes Market size is expected to reach USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to register a healthy CAGR of 5.5% during the forecast period. Demand for bone grafts and substitutes is increasing due to adoption of newer technologies and increasing demand for minimally invasive procedures.

    Availability of advanced products in varied shapes and sizes providing high osteoconductive and osteoinductive properties is supporting market growth. Moreover, growing adoption of minimally invasive procedures is spurring demand for bone grafts and substitutes. In minimally invasive procedures, large incisions and damage to muscles surrounding repair area can be significantly avoided. These techniques also reduce the duration of hospital stay and support rapid wound healing with lesser pain and surgical wounds. Minimally invasive total joint replacement and spine surgeries are some of the newly adopted procedures. Some of the companies in the bone grafts and substitutes market are DePuy Synthes; Medtronic PLC; Nuvasive, Inc.; Orthofix Holdings, Inc.; Wright Medical Group N.V.; AlloSource, Inc.; and Stryker Corp.

    Further key findings from the study suggest:

    • Increasing number of orthopedic surgeries and rising demand for minimally invasive surgeries are primary factors driving market growth
    • By material type, allografts accounted for the largest market share within the natural segment in 2016, mainly due to properties such as immediate structural support and osteoconductivity. Moreover, allografts do not require another surgery to harvest the bone, which results in reduced surgery time and wound healing, thus, attributing toward segment growth
    • North America is the leading regional market, followed by Europe. Rising awareness regarding commercially available products, higher healthcare expenditure, and availability of advanced healthcare infrastructure are prime factors responsible for the region’s expansion
    • Key players in the market include DePuy Synthes; Medtronic PLC; Nuvasive, Inc.; Orthofix Holdings, Inc.; Wright Medical Group N.V.; AlloSource, Inc.; and Stryker Corp.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/bone-grafts-substitutes-market


  • Angiography Equipment Market is Projected to Reach USD 16.2 Billion by 2026

    The global Angiography Equipment Market size is expected to reach USD 16.2 billion by 2026, according to a new report by Grand View Research, Inc. The market is expected to witness an exponential CAGR of 6.5% over the forecast period due to growing geriatric population, increasing prevalence of Cardiovascular Diseases (CVDs) with associated risk factors, technological advancements, and investments in the health tech sector. According to the World Health Organization (WHO) report, CVD is one of the leading causes of death in countries, such as U.S. and U.K.

    Coronary Artery Disease (CAD) is the most prevalent form of CVD. Through Global Hearts Initiative, the WHO is supporting governments in controlling cardiovascular risk factors, such as hypertension and diabetes. All these factors are projected to boost the market expansion over the forecast period. Rapid development of the diagnostic imaging modalities providing better visualization and assessment of CVD is also likely to drive the angiography devices market in the years to come.

    Geographically, North America held the largest market share in 2018 and is expected to maintain its position during the forecast period. Countries, such as Brazil and China, export the medical devices from U.S. owing to the high standard of quality. Due to favorable government regulations in developing countries, such as Japan and China, the Asia Pacific region is projected to expand at a healthy CAGR during the estimated period. For instance, reimbursement policy in Japan encourages the local manufacturers to provide advanced angiography diagnostic devices.

    Further key findings from the study suggest:

    • Angiography systems led the market in 2018 owing to the advancements in technology and interventional procedures in Cath labs
    • In 2018, X-ray held the largest share of the market due to technological developments offering superior-quality and high-resolution images without increasing radiation dose
    • Coronary angiography led the procedure segment due to increased prevalence of Cardiovascular Diseases (CVDs)
    • In 2018, diagnostic angiography accounted for the largest share of the application segment due to the growing complexity of the diseases
    • Some key companies in the industry are GE Healthcare; Koninklijke Philips N.V.; Siemens Healthineers; Boston Scientific Corporation; Abbott Laboratories; B. Braun Melsungen; Medtronic, Inc.; Angiodynamics; Cordis Corporation; and Shimadzu Corporation

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/angiography-device-market


  • Immunomodulators Market Size To Reach USD 233.7 Billion By 2025 | Grand View Research

    The global Immunomodulators Market is expected to reach USD 233.7 billion by 2025, according to a new study by Grand View Research, Inc. The market is anticipated to be predominantly driven by high R&D investments employed by the prominent companies, resulting into the large-scale production of new and therapeutically advanced drugs. This is believed to widen the influx of drugs at an unprecedented rate into the immunomodulators market hence providing highly efficacious treatment alternatives for numerous autoimmune and inflammatory diseases.

    In addition, increasing drugs resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.

    Furthermore, burgeoning presence of the key players is expected to promote the awareness levels pertaining to benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.

    In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.

    Further Key Findings From the Study Suggest:

    • Immunosuppressant held the largest share of the product segment in 2015, owing to increasing number of transplantation procedures and need to prevent organ rejection
    • Antibodies held the dominant share of immunosuppressant in 2015, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation
    • Immunostimulants expected to grow lucratively as a result of lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis
    • In 2015, North America dominated the global immunomodulators market owing to presence of wide number of established pharmaceutical companies involved in extensive commercialization
    • The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage
    • For instance, in March 2015, Novartis AG entered into research collaboration with Aduro Biotech. This was carried out to enhance its next generation cancer immunotherapy product pipeline

    Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/immunomodulators-market


  • Antiseptics and Disinfectants Market to Reach $27.99 Billion By 2026 | Grand View Research

    The global Antiseptics And Disinfectants Market size is expected to reach USD 27.99 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 6.7% during the forecast period. Increasing prevalence of Hospital-acquired Infections (HAIs), awareness about home cleanliness and the need for disinfection, and usage of endoscope reprocesses and surgical units across the globe are the key driving factors.

    Rising use of Gastrointestinal (GI) endoscopes and surgical units due to the increasing rate of surgeries across the globe is expected to drive the antiseptics and disinfectants market growth over the forecast period. GI endoscopy is one of the important tools for the treatment and identification of disorders of the gastrointestinal tract. Proper understandings of application to GI endoscopy and infection control is very much essential as it helps to prevent transmission of infection through endoscopes and lapses in reprocessing.

    Moreover, endoscopes need to be reprocessed appropriately as per the infection-control guidelines to lower the risk of acquiring environmental or patient-borne microorganisms. Thus, in such cases application of proper antiseptics and disinfectant solutions are very much essential to prevent transmission of infections. In addition, increasing rate of endoscopy is expected to surge the risk of getting such infections.

    For instance, as per the BMJ Publishing Group Ltd & British Society of Gastroenterology, published in 2018, the demand for gastrointestinal endoscopy has grown immensely for both and bowel cancer screening and symptomatic patients owing to which overall demand has doubled in many centers in U.K. over the last five years. Such factors are anticipated to drive the growth of antiseptics & disinfectants market.

    Further key findings from the report suggest:

    • In terms of revenue, quaternary ammonium compounds segment is expected to hold the largest market share over the forecast period. High prevalence of HAIs is the major factor driving the growth
    • Enzymatic cleaners are expected to witness the fastest growth over the forecast period. Increasing rate of surgeries is expected to drive the segment growth as the product is majorly used for disinfection of surgical kits
    • Asia-Pacific antiseptics and disinfectants market is expected to witness the fastest growth over the forecast period owing to the increasing number of hospitals and clinics
    • Prominent market players are BD, Johnson & Johnson, Novartis AG, and Cardinal Health.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/antiseptics-and-disinfectants-market


  • Circulating Tumor Cells (CTC) Market Size Worth $17.56 Billion By 2025

    The global Circulating Tumor Cells Market size is anticipated to reach USD 17.56 billion by 2025 growing at a CAGR of 15.0% during the forecast period, according to a new report by Grand View Research, Inc. Introduction of novel technologies for enumeration of CTC is anticipated to fuel the market growth. Rising cases of chronic oncology diseases that depend on CTC detection and analysis, as it has enormous potential in real-time monitoring of cancer therapy over methods like imaging technologies and tumor tissue biopsy, will also drive the market.

    Additionally, application of CTC as biomarkers for drug discovery is a promising factor for growth in the coming years. Utilization of the CTCs in the development of tumor-specific biomarkers to optimize the selection of targeted therapies and assessment of better response to the therapy is expected to support in the market growth. CTC enrichment accounted for the largest revenue share of the global market in 2018 and is expected to continue the dominance throughout the forecast period. This is due to extensive usage in oncology research establishments and high accuracy exhibited by this technology.

    Microchips technology is anticipated to register the highest CAGR owing to the introduction of cluster chip technology that helps capture the clusters of tumor cells for CTC quantitation. Cancer stem cell research segment accounts for the largest revenue share of the market. Properties of the cancer stem cells of self-renewal in replenishing the growing cancer is driving the attention of organizations and researchers in CTC cancer stem cell research segment.

    Further key findings from the study suggest:

    • Application of alterations in the expression profiles of EMT-associated transcriptional regulators and their molecular targets as biomarkers in EMT study is expected to serve as an impetus for diagnosis of tumor
    • North America led the CTC market in 2018 due to rising cases of cancer, oncology research funding, and favorable government initiatives for clinical diagnostic products
    • APAC is anticipated to witness the highest CAGR of over 16% from 2019 to 2025 due to infrastructural development in care centers and increased sales of CTC diagnostic tests
    • Rising need for new diagnosis methods for cancer has encouraged R&D in developing economies of APAC. This will help expand the region further
    • Fluxion Biosciences, Inc.; AdnaGen AG; Biocept, Inc.; Ikonisys, Inc.; and Sysmex Corp. are some of the key industry participants
    • Key companies focus on the development of novel technologies for CTC enrichment & detection through collaborations with hospitals and university-based research institutes to gain access to target population

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market


  • Global Downstream Processing Market is Projected to Grow $39.37 Billion by 2025

    he global Downstream Processing Market size is expected to reach USD 39.37 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 13.4% during the forecast period. Rising demand for biopharmaceuticals coupled with rapid developments in biotechnology and bioprocess techniques are anticipated to escalate the growth of market during the forecast period.

    In addition, key industry players are striving to capitalize potential avenues in the market by addressing challenges faced during scale by various downstream processing techniques. This is also leading to an increase in R&D expenditure of major manufacturers towards bioprocessing techniques. Furthermore, expanding base of contract manufacturing organizations is playing a vital role in the growth of the market. CMOs are providing process services to new market entrants, start-ups, and some large pharma companies, thereby helping them expand their pipeline to biopharma.

    Some of the prominent companies operating in the market are Thermo Fisher Scientific Inc.; General Electric Company (GE Healthcare); Sartorius Stedim Biotech S.A.; Merck KGaA (Merck Millipore); Danaher Corporation; 3M Company; Repligen; Boehringer Ingelheim International GmbH; Eppendorf AG; Lonza Group Ltd; Corning Corporation; Ashai Kasei; Dover Corporation (CPC (Colder Products Co.)); and Ferner PLC.

    Further key findings from the report suggest:

    • Surging demand for biosimilars is leading to upswing in the demand for better bioprocess solutions
    • Frequent usage of chromatography systems in downstream processes to achieve the highest level of purity of end product is one of the key factors that led to the largest share of this segment in 2017
    • On the basis of product, filters are expected to witness a lucrative CAGR during the forecast period owing to rising demand for membrane filters
    • Purification by chromatography was the highest revenue generating technique in 2017. The segment is estimated to retain its position through 2025 owing to high purity standards set for pharmaceuticals and other biologic products
    • Antibiotic production was the most prominent application segment in 2017 owing to high demand for antibiotics to cure a variety of diseases. Rigorous research in the field of therapeutic applications of monoclonal antibodies is contributing to the growth of the segment.

    Browse Details Report @ https://www.grandviewresearch.com/industry-analysis/downstream-processing-market


  • Clinical Trial Imaging Market to Reach $1.31 Billion by 2026 | Grand View Research

    The global Clinical Trial Imaging Market size is expected to reach USD 1.31 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.8% during the forecast period. Increasing spending on research and development activities to develop new drugs and therapies to treat chronic diseases is boosting market growth.

    Clinical trials assist in the development, registration, and eventually access of new drugs to patients. Imaging helps in the process of drug development by offering non-invasive evaluation of drug action and response of tumor to treatment. Functional imaging techniques are progressively being used in early phases of clinical trials to study initial effects of drug action on parts of tumor biology including metabolism, cellularity, and vascularity. 

    Contract Research Organizations (CROs) were the most prominent end-use segment in the market in 2017. Imaging modalities are used to determine indicators of pharmacological response to a therapy. Biomarkers and surrogate endpoints assist in obtaining quick results with good statistical power even in small sample sizes encouraging CROs to carryout multiple studies with reduced cost of operation.

    The market in Asia Pacific is projected to witness swift growth during the forecast period as the number of CROs and pharmaceutical organizations in the region are increasing in recent past due to low cost of labor and public and private funding offered in countries such as India and China. However, inaccessibility of trial protocols and poor quality of registered clinical trial data, results, and participant-level data undermined the potential benefits of clinical trial registration earlier. Nevertheless, emergence of national and regional registries and ICTRP have facilitated to overcome aforementioned barriers in APAC.

    Further key findings from the report suggest

    • North America dominated the market in 2017. Attaining compliance with registration requires a combination of international and local measures and remains a key challenge in many countries. However, U.S. FDA and other regulatory organizations have played a leading role in attaining accomplishments of trial registration to date and is likely to be supported in tackling such challenges in the near future
    • Some of the players operating in this market are Parexel International Corporation; Intrinsic Imaging; Radiant Sage; Icon PLC; Worldcare Clinical; Bioclinica Inc.; Navitas Life Sciences; Resonance Health; Ixico PLC; and Medpace.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/clinical-trial-imaging-market


  • Global Medical Waste Management Market Will Reach $33.4 Billion by 2025

    The global Medical Waste Management Market is expected to reach USD 33.4 billion by 2025, according to a new report by Grand View Research, Inc. The development of innovative manufacturing techniques in pharmaceuticals, medical devices is growing with rapid pace. The rise in hospitals, multispecialty clinics and diagnostic centers that require large number of inventories for day to day functioning is also leading to generation of more waste. Thus, overall growth in healthcare industry coupled with rising patient population requiring prolong medical and surgical aid is fueling the market growth.

    Rapid growth in initiatives by government to support and raise funds in effective waste management is anticipated to drive the market growth. These programs are conducted for creating awareness regarding the importance of systems for proper waste disposal. Additionally, taking steps to set standards and guidelines for the same is anticipated to propel the market growth.  

    The medical waste management involves high capital investment for managing hazardous by-products and disposal of infectious material. This disposal and recycling processes are associated with release of hazardous gases and compounds which may disturb the ecosystem and are likely to affect the industry growth.

    Further key findings from the study suggest:

    • The growing prevalence of infectious and chronic diseases coupled with overall growth of healthcare industry is augmenting the market growth
    • Most of the waste disposal treatments are performed offsite, however, to save cost and holding time, onsite treatment sites are expected to grow over the forecast period
    • The incineration segment accounted for the largest revenue share in 2016 however, other sophisticated non-incineration processes that are ecofriendly are projected to replace traditional incinerators
    • In 2016, North America dominated the global space with the largest revenue share of over 32.0% owing to growing healthcare industry and development of innovative techniques for disposal of material
    • Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding effective disposal and recycling.
    • Major players competing in the industry include but are not limited to Remondis Medison GmbH; Republic Services, Inc.; Sharp Compliance, Inc.; Stericycle, Inc.; Suez Environment, Inc.; Veolia Environment S.A.; Waste Management, Inc.

    Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/medical-waste-management-market


  • Intravascular Warming Systems Market to Reach USD 565.4 Million by 2025 | Grand View Research

    The Global intravascular warming systems market is expected to reach a value of USD 565.4 million by 2025, according to a new report by Grand View Research, Inc. Increasing number of surgical procedures is the most significant factor projected to boost the growth of the market during the forecast period. According to the WHO, around 266.2 to 359.5 million surgeries were performed globally in 2012 and this number is expected to increase in the near future. This in turn results in the need for intravascular warming products pre-, intra-, and postoperatively.

    Rising adoption of technologically advanced medical devices by operating rooms, ICUs, and emergency rooms is another major factor contributing to the growth of the market. The manufacturers are focusing on developing better in-line intravascular warming systems, which facilitate rapid flow of normothermic blood and intravenous fluids. The portability feature of these product also facilitates convenient usage during trauma or while transporting a patient to the hospital. Thus, the popularity of these devices is growing at a rapid pace, which is expected to propel the growth of the market.

    Further key findings from the study suggest:

    • Perioperative care was the largest revenue-generating segment in 2015 in the intravascular warming systems market. This is due to rising adoption of technologically advanced medical devices in operating rooms and ICUs
    • The acute care segment is expected to grow at highest rate during forecast period, owing to increasing adoption of intravascular warming systems for the treatment of accident and trauma patients
    • In 2015, operating rooms segment held the largest revenue share in this market, owing to the increasing number of surgical procedures worldwide
    • The emergency rooms segment is expected to grow at high pace during the study period, due to escalating number of patients requiring emergency medical care
    • North America held the largest share in the year 2015. The factors that can be attributed to such growth include well-developed healthcare infrastructure and high incidence of hypothermia & related death rates in countries like the U.S.
    • Asia Pacific is expected to grow at a lucrative CAGR owing to rising number of surgical procedures due to large number of road accident cases in India and China.
    • Some of the key players include Stryker Corp.; 3M; The 37 Company; Smiths Medical, Inc.; Geratherm Medical AG; Inditherm Plc.; Becton, Dickinson and Company; and Estill Medical Technologies, Inc.

    Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/intravascular-warming-systems-market


  • Epigenetics Market is Projected to Reach $22.05 Billion by 2025 | Grand View Research

    The global Epigenetics Market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. Growing prevalence of cancer and other diseases worldwide with epigenetic modification base is expected to drive the market during the forecast period.

    Diagnostic companies are coming up with new products such as antibodies specific for detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for development of therapeutic drugs, which will work in favor of the market.

    Presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by FDA for use in combination with Folfiri for treatment of patients with metastatic colorectal cancer.

    Technology advancements in the epigenetics industry are majorly focusing on detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene.

    Further key findings from the study suggest:

    • On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics
    • The kits segment is expected to post a CAGR of over 20.0% due to need for rapid and accurate detection techniques
    • DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. Rapid adoption of advanced techniques such as methylation sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment
    • North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for development of improved therapeutics
    • Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to presence of large target population coupled with high unmet clinical needs
    • Some of the major players of epigenetics market are Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation
    • Extensive R&D initiatives for development of novel drugs and presence of strong product pipeline are expected to further boost market growth over the forecast period.

    Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/epigenetics-market


connect